Shionogi v. Norwich Pharmaceuticals: XOFLUZA Generic Patent Dispute Settles
Shionogi, Inc. filed suit in the Delaware District Court against Norwich Pharmaceuticals over proposed generic versions of its influenza antiviral XOFLUZA (baloxavir marboxil), asserting US12064438B2. The parties reached a negotiated settlement after 247 days, resolving the dispute before trial.
XOFLUZA Generic Entry Blocked — or Licenced? Settlement Leaves Market Guessing
On 18 November 2024, Shionogi, Inc. filed a patent infringement action in the District of Delaware against Norwich Pharmaceuticals, Inc., alleging infringement of US12064438B2 in connection with Norwich’s ANDA seeking approval to market generic baloxavir marboxil tablets at the 40 mg and 80 mg strengths — the dosage forms sold under the XOFLUZA brand. Judge Maryellen Noreika was assigned to the case. XOFLUZA is a cap-dependent endonuclease inhibitor approved for the treatment of influenza and represents a significant commercial asset for Shionogi.
The case closed on 23 July 2025, just 247 days after filing, when the parties filed a stipulated consent order confirming that they had executed a private settlement agreement. The basis of termination is recorded as ‘Case Settled.’ The specific terms — including any licenced entry date, royalty structure, or market exclusivity provisions — are not disclosed in the public record. In ANDA litigation, settlements frequently involve negotiated launch dates that allow the brand holder to preserve near-term exclusivity while offering the generic a defined market entry window.
The pace of resolution — under nine months — is notably swift for Hatch-Waxman litigation, which ordinarily benefits from an automatic 30-month stay of FDA approval. The early settlement may suggest the parties identified a commercially acceptable entry timeline without litigating claim construction or validity, or that Norwich’s paragraph IV certification raised questions that made early resolution preferable. What the public record cannot confirm is whether Norwich secured a licenced launch date or agreed to stay off the market until patent expiry.
Filing to Case Settled in 247 days
247 days — resolved before trial; ANDA patent cases typically run 2–3 years to judgment
Case settled: what the agreed resolution means for each party
Stipulated settlement ends case without merits ruling
The parties filed a stipulation and consent order confirming execution of a private settlement agreement. No court ruling was issued on infringement, validity, or enforceability of US12064438B2. In Hatch-Waxman ANDA cases, this is the most common resolution — courts rarely reach trial in pharmaceutical patent disputes. The settlement agreement itself is not publicly filed; only the stipulated order of dismissal is part of the docket.
No merits adjudicationShionogi avoids invalidity risk, preserves enforcement record
By settling before claim construction or trial, Shionogi avoids the risk of an adverse validity or non-infringement ruling that could have weakened US12064438B2 against future ANDA filers. The settlement likely secures some period of continued market exclusivity for XOFLUZA. However, because terms are confidential, the degree of protection — and whether a licenced entry date was granted — cannot be confirmed from the public record.
Patent validity preservedNorwich avoids litigation cost — entry timeline uncertain
Norwich Pharmaceuticals avoids the expense and uncertainty of multi-year Hatch-Waxman litigation. In practice, ANDA settlements commonly include a negotiated authorised generic launch date or licence commencement — but neither a blocked-entry nor a licenced-entry conclusion can be confirmed here. If Norwich is a first-filer with paragraph IV certification, the terms of any 180-day exclusivity sharing or waiver would be material but remain undisclosed.
Terms confidentialXOFLUZA market position: short-term clarity, long-term questions
US12064438B2 remains valid and enforceable — no court has ruled otherwise. Other potential ANDA filers for baloxavir marboxil face the same patent barrier and will need to independently assess their paragraph IV exposure. The swift settlement may signal Shionogi’s confidence in the patent or Norwich’s pragmatism. Competitors and investors should monitor FDA ANDA approval status and any future paragraph IV certifications against this patent.
Patent still in forceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Shionogi, Inc. | Company | Pharmaceutical innovator — holder of US12064438B2 covering baloxavir marboxil (XOFLUZA)Search in Eureka ↗ |
| Defendant | NORWICH PHARMACEUTICALS, Inc. | Company | Generic pharmaceutical company seeking ANDA approval for baloxavir marboxil 40 mg and 80 mg tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Cameron Paul Clark | Attorney | Counsel for Shionogi, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Karen Jacobs | Attorney | Counsel for Shionogi, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Shionogi, Inc.Search in Eureka ↗ |
| Defendant counsel | Aaron Z. Savit | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Edward M. Mathias | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily DiBenedetto | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Jason T. Murata | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Karen Elizabeth Keller | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew J. Becker | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Nathan Roger Hoeschen | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Rebecca L. Clegg | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant counsel | Ross E. Blau | Attorney | Counsel for NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Defendant law firm | Shaw Keller LLP | Law Firm | Representing NORWICH PHARMACEUTICALS, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consent order confirms only that the parties executed a settlement agreement containing negotiated terms and conditions — no factual findings on infringement or validity of US12064438B2 were made. The phrasing is standard Hatch-Waxman settlement language and is deliberately neutral, offering no inference as to which party held the stronger litigation position. The settlement forecloses any precedential value for future ANDA challengers to this patent.
US12064438B2 — Baloxavir Marboxil (XOFLUZA) Formulation Patent
US12064438B2 (application number US16/764067) covers baloxavir marboxil formulations, the active ingredient in XOFLUZA — a cap-dependent endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza. XOFLUZA is notable for its single-dose oral regimen and a distinct mechanism of action from neuraminidase inhibitors such as oseltamivir. The patent’s application number and issue history suggest it belongs to a patent family protecting pharmaceutical composition and dosing aspects of the compound.
For pharmaceutical competitors, US12064438B2 represents a significant exclusivity barrier to the baloxavir marboxil market. The patent’s survival through this litigation — without any invalidity or non-infringement ruling — reinforces its status as a live enforcement risk. Any generic or biosimilar developer targeting the influenza antiviral space, particularly those considering ANDA filings for baloxavir marboxil tablets, should conduct a thorough freedom-to-operate analysis against this patent and its broader family before proceeding.
Should your team run an FTO analysis against US12064438B2?
Any pharmaceutical company developing or seeking regulatory approval for generic baloxavir marboxil tablets — at any dose strength — should treat US12064438B2 as a priority target in freedom-to-operate analysis. The patent has now survived an ANDA challenge without a merits ruling, meaning no court-validated design-around pathway exists. R&D and regulatory affairs teams at generic manufacturers should also review the broader patent family to identify related composition, method-of-use, and formulation claims that could independently block market entry.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US12064438B2 and its patent family, identify potential design-around opportunities, and flag related Shionogi patents covering baloxavir marboxil. Eureka can also surface active ANDA litigation and IPR proceedings in the influenza antiviral space, giving IP and regulatory teams a real-time view of the competitive patent environment before committing to an ANDA filing strategy.
Run a freedom-to-operate analysis on US12064438B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases Involving Influenza Antiviral Formulations
Explore comparable Hatch-Waxman infringement actions in the Delaware District Court targeting branded influenza antiviral formulation patents.
What this case signals for the pharmaceutical generics IP landscape
A sub-250-day settlement in an ANDA case involving a leading influenza antiviral reveals patterns worth tracking for any pharma IP team.
Early ANDA settlements signal strong brand patent positions
When Hatch-Waxman cases settle before claim construction, it typically suggests the patent holder holds a defensible position or the generic filer sees limited upside in a validity challenge. US12064438B2 emerges unscathed — no adverse ruling, no IPR, no weakened claims. Competitors should treat this patent as a live enforcement risk.
Confidential settlement terms create uncertainty for follow-on ANDA filers
With no public licence terms, other generic manufacturers seeking to enter the baloxavir marboxil market cannot infer a market-clearing date from this case. Each must independently evaluate their paragraph IV certification strategy and litigation exposure under US12064438B2 without the benefit of a public court ruling.
Shionogi v NORWICH — key questions answered
Shionogi asserted US12064438B2 (application number US16/764067), a patent covering baloxavir marboxil formulations — the active ingredient in XOFLUZA — against Norwich Pharmaceuticals’ ANDA for generic 40 mg and 80 mg baloxavir marboxil tablets.
The case was resolved by negotiated settlement. On 23 July 2025, the parties filed a stipulation and consent order confirming execution of a private settlement agreement. No court ruling on infringement or validity of US12064438B2 was issued. Settlement terms are not publicly disclosed.
XOFLUZA is an influenza antiviral developed by Shionogi that works by inhibiting cap-dependent endonuclease, offering a single-dose oral treatment. As a branded pharmaceutical, it is subject to Hatch-Waxman ANDA litigation when generic manufacturers file paragraph IV certifications asserting that listed patents are invalid or will not be infringed by their generic product.
No. The settlement produced no court ruling on validity or infringement. US12064438B2 remains valid and enforceable. The settlement cannot be relied upon as precedent by other ANDA filers, and the patent continues to pose an enforcement risk to any generic developer targeting the baloxavir marboxil market.
The case was filed in the District of Delaware and assigned to Judge Maryellen Noreika. The Delaware District Court is the most common venue for Hatch-Waxman ANDA patent litigation in the United States, given the concentration of pharmaceutical companies incorporated in the state.
PatSnap Eureka searches patents and litigation data to answer instantly.